Sanofi Secures EU Orphan Designation For Efdoralprin Alfa In Alpha-1 Antitrypsin Deficiency Related Emphysema

Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

• Additional orphan designation reinforces Sanofi's commitment to developing treatments for rare diseases
• Efdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care